Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial
Top Cited Papers
Open Access
- 19 December 2017
- journal article
- clinical trial
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 5 (1), 98
- https://doi.org/10.1186/s40425-017-0305-7
Abstract
Background We have previously shown that radiotherapy (RT) augments natural killer (NK) functions in pre-clinical models of human and mouse cancers, including sarcomas. Since dogs are an excellent outbred model for immunotherapy studies, we sought to assess RT plus local autologous NK transfer in canine sarcomas. Methods Dog NK cells (CD5dim, NKp46+) were isolated from PBMCs and expanded with irradiated K562-C9-mIL21 feeder cells and 100 IU/mL recombinant human IL-2. NK homing and cytotoxicity ± RT were evaluated using canine osteosarcoma tumor lines and dog patient-derived xenografts (PDX). In a first-in-dog clinical trial for spontaneous osteosarcoma, we evaluated RT and intra-tumoral autologous NK transfer. Results After 14 days, mean NK expansion and yield were 19.0-fold (±8.6) and 258.9(±76.1) ×106 cells, respectively. Post-RT, NK cytotoxicity increased in a dose-dependent fashion in vitro reaching ~ 80% at effector:target ratios of ≥10:1 (P < 0.001). In dog PDX models, allogeneic NK cells were cytotoxic in ex vivo killing assays and produced significant PDX tumor growth delay (P < 0.01) in vivo. After focal RT and intravenous NK transfer, we also observed significantly increased NK homing to tumors in vivo. Of 10 dogs with spontaneous osteosarcoma treated with focal RT and autologous NK transfer, 5 remain metastasis-free at the 6-month primary endpoint with resolution of suspicious pulmonary nodules in one patient. We also observed increased activation of circulating NK cells after treatment and persistence of labelled NK cells in vivo. Conclusions NK cell homing and cytotoxicity are increased following RT in canine models of sarcoma. Results from a first-in-dog clinical trial are promising, including possible abscopal effects.Keywords
Funding Information
- National Cancer Institute (R01 CA189209)
- University of California Cancer Research Coordinating Committee (CRR-13-201404)
- Society of Surgical Oncology
This publication has 44 references indexed in Scilit:
- Isolation and characterization of canine natural killer cellsVeterinary Immunology and Immunopathology, 2013
- Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cellsVeterinary Immunology and Immunopathology, 2013
- Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus documentVeterinary and Comparative Oncology, 2013
- Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer CellsPLOS ONE, 2012
- Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 2011
- Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface moleculesVeterinary Immunology and Immunopathology, 2010
- The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development PathwayPLoS Medicine, 2009
- Up on the tightrope: natural killer cell activation and inhibitionNature Immunology, 2008
- Activation and self‐tolerance of natural killer cellsImmunological Reviews, 2006
- Induction Of Lymphokine-Activated Killer (LAK) Activity in Canine Lymphocytes with Low Dose Human Recombinant InterIeukin-2in vitroCancer Biotherapy, 1994